Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)

BACKGROUND: On the basis of the results of two pivotal phase III clinical trials, eribulin mesylate is currently approved in EU for the treatment of advanced breast cancer (aBC) in patients who have previously received an anthracycline and a taxane in either the adjuvant or the metastatic setting, a...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :ESMO Open
Главные авторы: Orditura, Michele, Gravina, Adriano, Riccardi, Ferdinando, Diana, Anna, Mocerino, Carmela, Leopaldi, Luigi, Fabozzi, Alessio, Giordano, Guido, Nettuno, Raffaele, Incoronato, Pasquale, Barzelloni, Maria Luisa, Caputo, Roberta, Pisano, Agata, Grimaldi, Giuseppe, Genua, Geppino, Montesarchio, Vincenzo, Barbato, Enrico, Iodice, Giovanni, Lieto, Eva, Procaccini, Eugenio, Mabilia, Roberto, Febbraro, Antonio, Laurentiis, Michelino De, Ciardiello, Fortunato
Формат: Artigo
Язык:Inglês
Опубликовано: BMJ Publishing Group 2017
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5519815/
https://ncbi.nlm.nih.gov/pubmed/28761747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2017-000176
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы